Siemens Healthineers meets annual revenue and profit view, shares jump 8%
Adds China context, details and quotes from analyst presentation in paragraphs 4-10
By Marleen Kaesebier and Jörn Poltz
Nov 6 (Reuters) -Siemens Healthineers SHLG.DE met its annual revenue and profit growth forecast on Wednesday, as strength in its Imaging segment and U.S. cancer treatment unit Varian in the fourth quarter outweighed weakness in China, sending its shares up 8.1%.
The German medical technology company's comparable revenue growth was at 4.7% for the year ended Sept. 30, slightly missing analysts' forecast of 4.8%, according to a Vara Research-compiled consensus. It was at the lower end of the company's 4.5%-6.5% estimate.
Adjusted earnings before interest and taxes (EBIT) at 3.5 billion euros ($3.77 billion) also met analysts' estimates.
In China, revenue declined by a mid-single-digit percentage in the fourth quarter on currently delayed customer orders, the company said, but it sees "very strong" comparable revenue growth in the Americas.
Last week, rival medical devices maker Philips PHG.AS cut its 2024 sales outlook after flagging that demand for its products in China was hit by deteriorating consumer confidence in the country and the ongoing state-led anti-corruption campaign, which led to Chinese hospitals cutting back orders.
"We assume China revenue in the first half of fiscal year 2025 to decline mid-single-digit to high-single-digit percentage points," Siemens Healthineers CFO Jochen Schmitz said in a press briefing.
"In the second half of 2025, we assume revenue to be roughly at the level of the second half of fiscal 2024."
CEO Bernd Montag reiterated that the management believes China will stay attractive in the mid- and long-term.
The company expects a 5%-6% comparable revenue growth in 2025 and the adjusted basic earnings per share to be between 2.35 euros and 2.50 euros.
It also confirmed mid-term targets beyond 2025 and said it expects high-single-digits 2025 revenue growth in its Varian segment and a "mid-single-digits" revenue growth in Imaging, after the latter grew 7.7% in the fourth quarter, largely beating analyst expectations of 6.7%.
($1 = 0.9294 euros)
Reporting by Marleen Kaesebier and Joern Plotz; Editing by Sumana Nandy and Rashmi Aich
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
